Investment Firm Maintains ''Buy'' Rating For Major Biotech Company

HC Wainwright & Co. Maintains "Buy" Rating on Novavax, Lowers Price Target to $19.

Please note that this article is for informational purposes only and should not be considered financial advice. Always consult with a licensed financial professional before making any investment decisions.

In the dynamic world of biotechnology, Novavax, Inc. (NASDAQ: NVAX) remains a company to watch, despite recent adjustments in its price target by HC W…